Matthew Chen20 Jan 2021 10:16
I’d probably rely on comments made by the SPAC CEO, than some random deramper on an Internet forum...
“ Commenting on the Merger, Matthew Chen, Chief Executive Officer of Longevity said: "We are truly excited about the Merger with 4D. Our team reviewed many opportunities in a variety of industries, and determined that the Transaction with 4D would provide the greatest value to our shareholders. 4D is developing promising biotherapeutics to address unmet medical needs. We are impressed by 4D management team's track record in drug development and partnership building. We are very excited about the future prospects of the Enlarged Group."